Search Results

Semaglutide use in type 2 diabetes patients has been linked to a reduced risk of Alzheimer’s, suggesting new therapeutic possibilities. (Representational Image-Wikimedia Commons)
Ankur Deka
2 min read
Real-world evidence supports repurposing GLP-1 receptor agonists for Alzheimer’s prevention, with semaglutide showing significant benefits
With a four-year, $3.3 million grant from the National Institutes of Health (NIH), researchers from Case Western Reserve University will study whether certain brain proteins may play a role in development of Alzheimer's disease. (Representational image: Pixabay)
MBT Desk
2 min read
National Institutes of Health (NIH)-backed study will examine the potential function of epitope (Eph) receptors in Alzheimer’s disease
New research suggests outdoor light pollution at night may be a significant risk factor for Alzheimer’s disease, especially in individuals under 65. (Representational Image: Wikimedia Commons)
Ankur Deka
3 min read
New research highlights a potential connection between nighttime light exposure and Alzheimer's disease, particularly among younger individuals
Neurologists diagnose cognitive impairment through clinical exams of memory and thinking skills. To confirm Alzheimer's disease, evidence of specific brain changes is needed, usually obtained via brain scans or spinal taps. (Representational Image: Unsplash)
MBT Desk
4 min read
Varying Accuracy of Diagnostic Blood Tests for Alzheimer's Disease
In a new study, a molecule identified and synthesized by UCLA Health researchers was shown to restore cognitive functions in mice with symptoms of Alzheimer’s disease by effectively jumpstarting the brain's memory circuitry. (Representational image: Pixabay)
MBT Desk
4 min read
A molecule identified and synthesized by UCLA Health researchers was shown to restore cognitive functions.
The FDA approved a new Alzheimer’s disease treatment today called donanemab (brand name Kisunla), after it was reviewed and recommended by an advisory panel earlier this year. (Representational Image: Pixabay)
MBT Desk
2 min read
The FDA approved a new Alzheimer’s disease treatment called donanemab (brand name Kisunla), after it was reviewed and recommended by an advisory panel earlier this year.
Read More
logo
Medbound
www.medboundtimes.com